Electronic Supplementary Material (ESI) for Dalton Transactions. This journal is © The Royal Society of Chemistry 2017

A General Strategy to Add Diversity to Ruthenium Arene Complexes with

Bioactive Organic Compounds via a Coordinated (4-

Hydroxyphenyl)diphenylphosphine Ligand

Lorenzo Biancalana, Lucinda K. Batchelor, Alice De Palo, Stefano Zacchini, Guido Pampaloni, Paul J. Dyson, Fabio Marchetti

Supporting Information

Table of contents	
General experimental details	S2
IR and NMR spectra of bioactive acids and their corresponding acyl	S3-S6
chlorides	
Synthesis and characterization of the phosphine ligands	S7-S10
Synthesis and characterization of ruthenium compounds	S11-S18
Table S1. Comparison of IR and NMR data	S19
X-ray crystallography	S20
Stability studies in DMSO-water solutions	S21-S29
Cell culture and cytotoxicity studies	S30-S31
References	S32

General experimental details

RuCl₃·3H₂O (99.9%) was purchased from Strem and the organic reactants were obtained from Alfa Aesar, Sigma Aldrich or TCI Europe and were of the highest purity available. The following reagents were stored under nitrogen or argon as received: aspirin (ASP-CO₂H), ethacrynic acid (EA-CO₂H), 4-bromophenol (under protection from the light), tert-butyldimethylsilyl chloride (TBDMSCl), chlorodiphenylphosphine, oxalyl chloride (4°C), butyl lithium (2.5 M in hexanes; 4°C), tetrabutylammonium fluoride (TBAF, 1 M in THF; 4°C), triethylamine and ethyl(diisopropylamino)carboxydiimide hydrochloride (EDCI·HCl; -20°C). Tributylamine was distilled from BaO and stored under nitrogen. $[(\eta^6-p-cymene)RuCl_2]_2$ was prepared according to a literature method.¹ All reactions were carried out under a nitrogen atmosphere using standard Schlenk techniques and solvents distilled from appropriate drying agents. Once isolated, p- $C_6H_4Br(OSiMe_2^{t}Bu)$, $PPh_2(4-C_6H_4OSiMe_2^{t}Bu)$, $PPh_2(4-C_6H_4OH)$, L2 and L4 were stored under nitrogen, all of the other products being air stable. Silica gel (Merck, 70-230 mesh) was dried at 150 °C overnight and stored under nitrogen. NMR spectra were recorded at 298 K on a Bruker Avance II DRX400 instrument equipped with a BBFO broadband probe. Chemical shifts (expressed in parts per million) are referenced to the residual solvent peaks (¹H, ¹³C) or to external standard (³¹P to 85% H₃PO₄). Spectra were assigned with the assistance of ${}^{1}H{}^{31}P{}$. DEPT-135 spectra and ${}^{1}H{}^{-1$ (COSY), ¹H-¹³C (gs-HSOC and gs-HMBC) correlation experiments.² Infrared spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer equipped with a UATR sampling accessory. Infrared spectra of CH₂Cl₂ solutions were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with a CaF₂ liquid transmission cell. Carbon, hydrogen and nitrogen analysis was performed on a Carlo Erba mod. 1106 instrument. Melting points were determined on a STMP3 Stuart scientific instrument with a capillary apparatus.

IR and NMR spectra of bioactive acids and their corresponding acyl chlorides

Aspirin (ASP-CO₂H) and Aspirin acyl chloride (ASP-COCl)

Chart S1. Structures of ASP-CO₂H (left) and ASP-COCl (right) (numbering refers to carbon atoms).



*ASP-CO*₂*H*. Colourless solid. IR (solid state): $\tilde{v}/cm^{-1} = 3200-2700w$ -br, 2869w, 2832w, 2697w, 2658w, 2586w, 2545w, 1750s ($v_{C8=O}$), 1681s ($v_{C1=O}$), 1605s, 1575w, 1483w, 1456s, 1436w, 1418m, 1369m, 1304s, 1291s, 1258m, 1218s, 1184s, 1135m, 1093m, 1086m-sh, 1038m, 1012m, 970m, 915s, 885m-sh, 839s, 803s, 789m, 753s, 704s, 666m. IR (CH₂Cl₂): $\tilde{v}/cm^{-1} = 3625w$, 1770s ($v_{C8=O}$), 1738m ($v_{C1=O}$), 1701s, 1608m, 1487sh, 1370m, 1222s-sh, 1189s, 1086w, 1068w, 1017m. ¹H NMR (CDCl₃): δ /ppm = 10.7 (br, 1H, OH), 8.13 (d, ³J_{HH} = 7.7 Hz, 1H, C3-H), 7.63 (t, ³J_{HH} = 7.6 Hz, 1H, C4-H), 7.14 (d, ³J_{HH} = 8.0 Hz, 1H, C6-H), 2.35 (s, 3H, C9-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 170.3 (C1 or C8), 169.9 (C1 or C8), 151.4 (C7), 135.0 (C5), 132.7 (C3), 126.3 (C4), 124.1 (C6), 122.4 (C2), 21.1 (C9).

ASP-COCl. Colourless solid. IR (CH₂Cl₂): $\tilde{\nu}$ /cm⁻¹ = 1780s-sh ($\nu_{C1=O}$), 1768s ($\nu_{C8=O}$), 1675w, 1603m, 1577w, 1477m-sh, 1451m-sh, 1371m, 1123m-sh, 1193s, 1162m, 1115w, 1101w. ¹H NMR (CDCl₃): δ /ppm = 8.25 (d, ³J_{HH} = 7.9 Hz, 1H, C3-H), 7.70 (m, 1H, C5-H), 7.43 (m, 1H, C4-H), 7.18 (d, ³J_{HH} = 7.9 Hz, 1H, C6-H), 2.35 (s, 3H, C9-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 169.2 (C8), 164.7 (C1), 150.4 (C7), 136.1 (C5), 134.4 (C3), 126.6 (C4), 126.5 (C6), 124.4 (C2), 20.8 (C9) ppm.

Ibuprofen (IBU-CO₂H) and Ibuprofen acyl chloride (IBU-COCl)

Chart S2. Structures of IBU-CO₂H (left) and IBU-COCl (right) (numbering refers to carbon atoms).



*IBU-CO*₂*H*. Crystalline colourless solid. IR (solid state): $\tilde{v}/cm^{-1} = 3090w$, 3045w, 3020m, 2992m, 2980m, 2954m, 2922m, 2869m, 2728w, 2632w, 2602w, 2542w, 1712s ($v_{C=0}$), 1507m, 1462m,

1450m, 1442w, 1418s, 1379m, 1365w, 1329m-sh, 1321m, 1268m, 1230s, 1183s, 1168m, 1123m, 1092w, 1073m, 1008m, 970w, 935m, 879w, 865s, 849m, 834w, 820w, 779s, 747w, 691w, 667s. IR (CH₂Cl₂): $\tilde{\nu}$ /cm⁻¹ = 2870m, 1747w and 1708s ($\nu_{C=O}$), 1513w. ¹H NMR (CDCl₃): δ /ppm = 10.5 (br, 1H, OH), 7.23 (d, ³*J*_{HH} = 8.0 Hz, 2H, C5-H), 7.11 (d, ³*J*_{HH} = 8.0 Hz, 2H, C6-H), 3.71 (q, ³*J*_{HH} = 7.2 Hz, 1H, C2-H), 2.45 (d, ³*J*_{HH} = 7.2 Hz, 2H, C8-H), 1.85 (non, ³*J*_{HH} = 6.7 Hz, 1H, C9-H), 1.51 (d, ³*J*_{HH} = 7.2 Hz, 3H, C3-H), 0.90 (d, ³*J*_{HH} = 6.6 Hz, 6H, C10-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 180.9 (C1), 141.0 (C7), 137.1 (C4), 129.5 (C6), 127.4 (C5), 45.2 (C8), 45.1 (C2), 30.3 (C9), 22.5 (C10), 18.2 (C3).

IBU-COC1. Colourless liquid. IR (CH₂Cl₂): $\tilde{v}/cm^{-1} = 1785s (v_{C=0}), 1513w.$

Ethacrynic acid (EA-CO₂H) and Ethacrynic acyl chloride (EA-COCl)

Chart S3. Structures of EA-CO₂H (left) and EA-COCl (right) (numbering refers to carbon atoms).



*EA-CO*₂*H*. Colourless solid. IR (solid state): \tilde{v} /cm⁻¹ = 3300-2550w-br, 2968m, 2938w, 2882w, 1724s ($v_{C1=O}$), 1671s and 1661s ($v_{C9=O}$), 1622w, 1585s ($v_{C10=C11}$), 1556w-sh, 1474s, 1455m-sh, 1424m, 1387m, 1370m, 1360m, 1340w, 1307m-sh, 1279s, 1265s, 1249s, 1205s, 1124m, 1078s, 1005m, 956m-sh, 945s, 930m, 909s, 849w, 825w, 799s, 768s, 736w, 721m, 690m. IR (CH₂Cl₂): \tilde{v} /cm⁻¹ = 3500-3400w-br, 1780m, 1761m and 1741s ($v_{C1=O}$), 1667s ($v_{C9=O}$), 1588s ($v_{C10=C11}$), 1470s-sh, 1385m-sh, 1340w, 1123w, 1083s. ¹H NMR (CDCl₃): δ /ppm = 7.75 (s-br, 1H, OH), 7.15 (d, ³J_{HH} = 5.3 Hz, 1H, C7-H), 6.81 (d, ³J_{HH} = 4.9 Hz, 1H, C8-H), 5.95 (s, 1H, C11-H), 5.60 (s, 1H, C11-H'), 4.80 (s, 2H, C2-H), 2.46 (q, ³J_{HH} = 7.1 Hz, 2H, C12-H), 1.14 (t, ³J_{HH} = 7.3 Hz, 3H, C13-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 196.2 (C9), 172.6 (C1), 155.2 (C3), 150.3 (C10), 134.2 (C4), 131.7 (C5), 129.1 (C11), 127.0 (C7), 123.5 (C6), 111.0 (C8), 65.9 (C2), 23.5 (C12), 12.5 (C13).

EA-COCl. Pale yellow liquid. IR (CH₂Cl₂): $\tilde{v}/cm^{-1} = 1848m$ and 1806s ($v_{C1=O}$), 1668s ($v_{C9=O}$), 1587s ($v_{C10=C11}$), 1468s-sh, 1385m-sh, 1340w, 1216m-sh, 1127w, 1088m, 1049m.

Indomethacin (IM-CO₂H) and Indomethacin acyl chloride (IM-COCl)

Chart S4. Structures of IM-CO₂H (left) and IM-COCl (right) (numbering refers to carbon atoms).



*IM-CO*₂*H*. Colourless solid. IR (solid state): $\tilde{v}/cm^{-1} = 3024w$, 2967w, 2928w, 2832w, 1713s (v_{C1=O}), 1689s (v_{C13=O}), 1614w, 1603w, 1588w, 1478m, 1455m, 1426w, 1412w, 1396w, 1371m-sh, 1359m, 1306s, 1290m-sh, 1261w, 1233s-sh, 1222s, 1189m, 1148m, 1085m, 1067s, 1028m, 1012w, 925w, 906w, 854w, 838m, 832s, 769w, 752s, 736w, 702w, 691w, 658w. IR (CH₂Cl₂): $\tilde{v}/cm^{-1} = 1713s$ (v_{C1=O}), 1685s (v_{C13=O}), 1595m, 1479s-sh, 1369m, 1358m, 1315s-sh, 1090m, 1068w, 1036w, 1015w. ¹H NMR (CDCl₃): δ /ppm = 7.66 (d, ³*J*_{HH} = 8.5 Hz, 2H, C15-H), 7.47 (d, ³*J*_{HH} = 8.5 Hz, 2H, C16-H), 6.95 (d, ⁴*J*_{HH} = 2.4 Hz, 1H, C5-H), 6.85 (d, ³*J*_{HH} = 9.0 Hz, 1H, C9-H), 6.67 (dd, ³*J*_{HH} = 9.0 Hz, ⁴*J*_{HH} = 2.5 Hz, 1H, C8-H), 3.82 (s, 3H, C7-H), 3.69 (s, 2H, C2-H), 2.38 (s, 3H, C12-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 176.8 (C1), 168.4 (C13), 156.2 (C6), 139.5 (C17), 136.4 (C4), 133.9 (C14), 131.3 (C15), 130.9 (C10 or C11), 130.6 (C10 or C11), 129.3 (C16), 115.1 (C9), 111.9 (C3), 111.8 (C8), 101.4 (C5), 55.9 (C7), 30.1 (C2), 13.4 (C12).

IM-COCl. Pale yellow solid. IR (solid state): $\tilde{v}/cm^{-1} = 3097w$, 3072w, 3060w, 3038w, 3000w, 2967w, 2941w, 2903w, 2835w, 1790s ($v_{C1=O}$), 1683s ($v_{C13=O}$), 1621w, 1597m, 1488w-sh, 1477m, 1465s, 1442m, 1434m, 1402w, 1371w, 1349s, 1324s, 1291m, 1260m, 1229s, 1213s, 1192w, 1178w, 1153s, 1139m, 1085s, 1066s, 1034s, 1013s, 991s, 947s, 898m, 850m, 825m, 800s, 789s, 755s, 740m, 714m, 691s, 657w. IR (CH₂Cl₂): $\tilde{v}/cm^{-1} = 1795m$ ($v_{C1=O}$), 1687s ($v_{C13=O}$), 1595m, 1479s-sh, 1371m, 1357m, 1315s-sh, 1091s, 1069w, 1037w, 1015m.

Diclofenac (DF-CO₂H) and Diclofenac acyl chloride (DF-COCl)

Chart S5. Structures of DF-CO₂H (left) and DF-COCl (right) (numbering refers to carbon atoms).



*DF-CO*₂*H*. Colourless solid. IR (solid state): $\tilde{v}/cm^{-1} = 3500-3100w$ -br, 3322m (v_{NH}), 3071w, 3030w, 2971m, 2927w, 2882w, 2724w, 2636w, 2609w, 2584w, 2562w, 1690s ($v_{C=0}$), 1587m, 1577m, 1568m, 1506s, 1495m-sh, 1479m, 1452s, 1421s, 1412s, 1380m, 1321m, 1303s, 1281s, 1272s, 1199m, 1158s, 1130m, 1092m, 1070w, 1045w, 936s, 890w, 861m, 835m, 817w, 775m,

765s, 751m, 739s, 709s. ¹H NMR (Acetone-d⁶): δ /ppm = 10.8 (br, 1H, OH), 7.46 (d, ³*J*_{HH} = 7.9 Hz, 2H, C11-H), 7.29 (d, ³*J*_{HH} = 7.3 Hz, 1H, C4-H), 7.20 (s, 1H, NH), 7.17–7.08 (m, 2H, C6-H and C12-H), 6.94 (t, ³*J*_{HH} = 7.3 Hz, 1H, C5-H), 6.47 (d, ³*J*_{HH} = 7.9 Hz, 1H, C7-H), 3.82 (s, 2H, C2-H). ¹³C{¹H} NMR (Acetone-d⁶): δ /ppm = 173.9 (C1), 143.9 (C8), 138.8 (C9), 131.8 (C4), 130.4 (C10), 129.9 (C11), 128.6 (C6), 125.8 (C3), 125.6 (C12), 122.6 (C5), 118.3 (C7), 38.6 (C2).

DF-COCl. In a 50 mL schlenk tube, (COCl)₂ (0.10 mL, 1.2 mmol) was added to a solution of DF-CO₂H (73 mg, 0.25 mmol) in CH₂Cl₂ (6 mL). The resulting colourless suspension was stirred at room temperature for 1.5 hours and the progress of reaction was monitored by TLC. Therefore, volatiles were carefully removed in vacuo (60°C) and a pale yellow solid was obtained. IR (solid state): $\tilde{\nu}/\text{cm}^{-1} = 1731\text{s}$ ($\nu_{\text{C=O}}$), 1613m, 1563w, 1489m, 1461m-sh, 1455m, 1436m, 1361m, 1317w, 1302m, 1239m, 1205w, 1191m, 1171m, 1148m, 951m, 859w, 781s, 748s, 670m. ¹H NMR (CDCl₃): δ /ppm = 7.51 (d, ³*J*_{HH} = 8.0 Hz, 2H, C11-H), 7.40-7.32 (m, 2H, C4-H and C6-H), 7.21 (t, ³*J*_{HH} = 7.6 Hz, 1H, C12-H), 7.10 (t, ³*J*_{HH} = 7.4 Hz, 1H, C5-H), 6.41 (d, ³*J*_{HH} = 7.7 Hz, 1H, C7-H), 3.78 (s, 2H, C2-H). ¹³C NMR (CDCl₃): δ /ppm = 173.7 (C1), 143.4 (C8), 135.6 (C9), 130.9 (C4), 130.6 (C10), 129.1 (C11), 128.0 (C6), 124.9 (C12), 124.4 (C3), 123.2 (C5), 109.2 (C7), 35.8 (C2).

Reactions of 1 with DF-COCl and Et_3N under different experimental conditions led to mixtures of products that did not contain 6.

Valproic acid (VP-CO₂H)

Chart S6. Structure of VP-CO₂H (numbering refers to carbon atoms).



Colourless liquid. IR (liquid film): $\tilde{v}/cm^{-1} = 3300-2800w$ -br, 2959m, 2935m, 2874m, 1702s ($v_{C=O}$), 1466w, 1416w, 1381w, 1344w, 1290w, 1279w, 1251m, 1213m, 1153w, 1108w, 941w, 820w, 770w-sh, 748w. ¹H NMR (CDCl₃): δ /ppm = 11.4 (s-br, 1H, OH), 2.37 (m, J = 9.2, 5.2 Hz, 1H, C2-H), 1.68–1.55 (m, 2H) and 1.50–1.40 (m, 2H, C3-H), 1.40–1.27 (m, 4H, C4-H), 0.91 (t, ${}^{3}J_{HH} = 7.2$ Hz, 6H, C5-H). ${}^{13}C{}^{1}H{}$ NMR (CDCl₃): δ /ppm =183.6 (C1), 45.3 (C2), 34.5 (C3), 20.7 (C4), 14.1 (C5)

Synthesis of PPh₂(4-C₆H₄OH), L1

Chart S7. Structure of PPh₂(4-C₆H₄OH) (numbering refers to carbon atoms).



The three-step procedure for the synthesis of PPh₂(4-C₆H₄OH) was adapted from the literature.

Step 1.³ In a 100 mL Schlenk tube, Et₃N (2.0 mL, 14 mmol) and TBDMSCl (2.36 g, 15.7 mmol) were added to a solution of 4-bromophenol (2.20 g, 12.7 mmol) in CH₂Cl₂ (20 mL). The pale yellow suspension was stirred at room temperature for 18 hours under protection from the light and the progress of reaction was monitored by TLC. The resulting mixture (pale yellow solution/colourless suspension) was extracted with H₂O (50 mL), the organic phase was separated and volatiles removed in vacuo. The residue was redissolved in hexane (15 mL) and extracted with H₂O (2x50 mL). The organic phase was dried with Na₂SO₄, filtered and volatiles were removed in vacuo (40°C). The compound *p*-C₆H₄Br(OSiMe₂^{*t*}Bu) was obtained as a colourless liquid. Yield: 3.49 g, 96%. ¹H NMR (CDCl₃): δ /ppm = 7.32 (d, ³J_{HH} = 8.6 Hz, 2H, CH), 6.71 (d, ³J_{HH} = 8.6 Hz, 2H, CH), 0.97 (s, 9H, CMe₃), 0.18 (s, 6H, SiMe₂).

Step 2.⁴ In a 100 mL schlenk tube, ^{*n*}BuLi (2.5 M in hexanes; 5.0 mL, 12.5 mmol) was slowly added (15 min) to a solution of *p*-C₆H₄Br(OSiMe₂'Bu) (3.49 g, 12.1 mmol) in Et₂O (35 mL) at 0°C under vigorous stirring. The resulting pale yellow solution was allowed to heat to room temperature and stirred for 1.5 hours then Ph₂PCl (2.4 mL, 13 mmol) was slowly added (15 min) at 0°C. The resulting suspension was allowed to heat to room temperature and stirred for 18 hours. Therefore the reaction mixture was loaded on top of a SiO₂ column (h 4.5, d 4.5 cm) and eluted with Et₂O (80 mL). Volatiles were removed in vacuo and PPh₂(4-C₆H₄OSiMe₂'Bu) was obtained as a colourless solid. Yield: 3.82 g, 80%. ¹H NMR (CDCl₃): δ /ppm = 7.38 (s, 10H, Ph₂), 7.32 (*pseudo*-t, ³*J*_{HH} = ³*J*_{HP} = 7.0 Hz, 2H, CH), 6.93 (d, ³*J*_{HH} = 8.1 Hz, 2H, CH), 1.08 (s, 9H, CMe₃), 0.30 (s, 6H, SiMe₂). ³¹P{¹H} NMR (CDCl₃): δ /ppm = -6.8.

Step 3.⁴ In a 100 mL round-bottom schlenk flask, TBAF (1 M in THF; 15 mL, 15 mmol) was slowly added (15 min) to a solution of PPh₂(4-C₆H₄OSiMe₂^{*t*}Bu) (3.40 g, 8.66 mmol) in Et₂O (20 mL) at 0°C under vigorous stirring. The resulting pale yellow solution was allowed to heat to room temperature and stirred for 16 hours then 37% HCl (1.3 mL, *ca.* 16 mmol) was added dropwise at 0°C. The reaction mixture was allowed to heat to room temperature and stirred for 5 hours, therefore volatiles were removed in vacuo. The oily residue was dissolved in Et₂O (10 mL) and the

solution was extracted with H₂O (3x25 mL). The organic phase was separated, reduced to a small volume in vacuo and loaded on top of a SiO₂ column (h 6, d 4.5 cm). The title compound was eluted with Et₂O (100 mL) then volatiles were removed in vacuo. The resulting oily residue was redissolved in a small volume of hexane and dried in vacuo, yielding PPh₂(4-C₆H₄OH) as a colourless solid. Yield: 1.72 g, 71%. IR (solid state): $\tilde{\nu}$ /cm⁻¹ = 3400-3100w-br (v_{OH}), 3070w, 3054w, 2918w, 2850w, 1598m, 1582m, 1498m, 1477w, 1434m, 1362w, 1329w, 1174m, 822s, 743s, 695s. ¹H NMR (CDCl₃): δ /ppm = 7.41–7.30 (m, 10H, Ph), 7.26 (t, ³J_{HH} = ³J_{HP} = 8.1 Hz, 2H, C3-H), 6.88 (d, ³J_{HH} = 8.4 Hz, 2H, C2-H), 5.96 (s-br, 1H, OH). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 156.5 (C1), 137.5 (d, ¹J_{CP} = 9.0 Hz, C5), 135.9 (d, ²J_{CP} = 21.1 Hz, C3), 133.4 (d, ²J_{CP} = 18.9 Hz, C6), 128.7 (C8), 128.5 (d, ³J_{CP} = 6.9 Hz, C7), 115.9 (d, ³J_{CP} = 8.2 Hz, C2). ³¹P{¹H} NMR (CDCl₃): δ /ppm = -6.8 ppm.

Synthesis of PPh₂(4-C₆H₄OCO-ASP), L2

Chart S8. Structure of L2 (numbering refers to carbon atoms).



In order to prepare ASP-COCl,⁵ in a 50 mL schlenk tube (COCl)₂ (0.25 mL, 2.9 mmol) and one drop of DMF were added to a solution of ASP-CO₂H (119 mg, 0.658 mmol) in CH₂Cl₂ (7 mL). The resulting colourless solution was stirred at room temperature for 1 hour then volatiles were carefully removed in vacuo (50°C). The colourless solid obtained was dissolved in CH₂Cl₂ (7 mL); IR spectrum of this solution confirmed the complete conversion to the acyl chloride (ASP-COCl). Therefore PPh₂(4-C₆H₄OH) (190 mg, 0.68 mmol) and Et₃N (0.11 mL, 0.79 mmol) were introduced. The resulting pale yellow-brown solution was stirred at room temperature for 20 hours then volatiles were removed in vacuo. The colourless solid residue was suspended in Et₂O (20 mL) and extracted with O₂-free H₂O (4x20 mL). The phases were separated and volatiles were removed in vacuo from the organic phase. The residue was dissolved in a small volume of Et₂O and loaded on top of a SiO₂ column, followed by elution with hexane:Et₂O (1:1 v/v). The title compound was obtained as an extremely-air sensitive, colourless solid after solvent removal in vacuo (RT), along with some non P-containing by-products. ¹H NMR (CDCl₃): δ /ppm = 8.21 (d, ³J_{HH} = 7.9 Hz, 1H, C7-H), 7.69–7.61 (m, 1H, C5-H), 7.44–7.29 (m, 12H, Ph₂P + C12-H), 7.21 –7.15 (m, 3H, C11-H and C6-H), 7.08 (d, ${}^{3}J_{\text{HH}} = 8.8$ Hz, 1H, C4-H), 2.32 (s, 3H, C1-H). ${}^{13}C{}^{1}H$ NMR (CDCl₃): δ /ppm = 169.9 (C2), 162.9 (C9), 151.4 (C3 or C10), 151.3 (C3 or C10), 137.1 (d, ${}^{1}J_{CP}$ = 10.5 Hz, C14), 134.8 (C5), 135.2 (d, ${}^{2}J_{CP}$ = 20.6 Hz, C12), 133.9 (d, ${}^{2}J_{CP}$ = 19.6 Hz, C15), 132.8 (C7), 129.0

(C17), 128.7 (d, ${}^{3}J_{CP} = 6.9$ Hz, C16), 126.4 (C6), 124.2 (C4), 122.6 (C8), 122.0 (d, ${}^{3}J_{CP} = 7.5$ Hz, C11), 21.2 (C1). ${}^{31}P{}^{1}H$ NMR (CDCl₃): δ /ppm = -6.1 ppm.

The compound completely converted into the corresponding phosphine oxide $({}^{31}P{}^{1}H)$ NMR (CDCl₃): δ /ppm = 31.7) and other by-products upon 20 minutes of air exposition of the solid.

Synthesis of PPh₂PPh₂(4-C₆H₄OCO-EA), L4

Chart S9. Structure of L4 (numbering refers to carbon atoms).



A solution of PPh₂(4-C₆H₄OH) (190 mg, 0.68 mmol) and EA-CO₂H (233 mg, 0.768 mmol) in CH₂Cl₂ (15 mL) was treated with EDCI·HCl (200 mg, 1.04 mmol) and then with DMAP (16 mg, 0.13 mmol). The resulting colourless solution was stirred at room temperature for 24 hours. Volatiles were removed in vacuo (RT) and a colourless foamy solid was obtained. The solid was suspended in Et₂O (20 mL) for 1 hour, then the liquid was transferred into another flask; the extraction procedure was repeated three times. The title compound was obtained as an extremely-air sensitive, colourless solid after solvent removal in vacuo (RT), along with some non P-containing by-products. Yield: 230 mg, 60%. ¹H NMR (CDCl₃): δ /ppm = 7.39–7.28 (m, 12H, Ph₂P + C16-H), 7.18 (d, ³J_{HH} = 8.5 Hz, 1H, C11-H), 7.13 (d, ³J_{HH} = 8.0 Hz, 2H, C15-H), 6.91 (d, ³J_{HH} = 8.5 Hz, 1H, C11-H), 5.62 (s, 1H, C4-H'), 5.02 (s, 2H, C12-H), 2.49 (q, ³J_{HH} = 7.2 Hz, 2H, C2-H), 1.17 (t, ³J_{HH} = 7.4 Hz, 3H, C1-H). ¹³C {¹H} NMR (CDCl₃): δ /ppm = 195.9 (C5), 166.3 (C13), 155.4 (C9), 150.5 (C3 or C14), 150.3 (C3 or C14), 136.9 (d, ¹J_{CP} = 10.3 Hz, C18), 135.2 (d, ²J_{CP} = 20.4 Hz, C16), 134.4 (C8), 133.8 (d, ²J_{CP} = 19.5 Hz, C19), 131.8 (C7), 129.8 (C21), 128.9 (C4), 128.8 (d, ³J_{CP} = 6.8 Hz, C20), 126.9 (C11), 123.7 (C6), 121.4 (d, ³J_{CP} = 7.1 Hz, C15), 111.2 (C10), 66.5 (C12), 23.5 (C2), 12.5 (C1). ³¹P{¹H} NMR (CDCl₃): δ /ppm = -6.3.

The compound rapidly converted into the corresponding phosphine oxide $({}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 28.2$) and other by-products upon brief air exposition of the solid.

Synthesis of O=PPh₂(4-C₆H₄OH)⁶

Chart S10. Structure of O=PPh₂(4-C₆H₄OH) (numbering refers to carbon atoms).



A solution of PPh₂(4-C₆H₄OH) (240 mg, 0.86 mmol) in acetonitrile (15 mL) was treated with an excess of H₂O_{2,aq} (30% w/w, ca. 15 mmol), and the resulting mixture was allowed to stir at room temperature for 24 hours. Then the volatiles were removed in vacuo, and the colourless residue was dried in vacuo over P₂O₅ for 5 hours. Yield 202 mg, 80%. ¹H NMR (CH₃OD): δ /ppm = 7.67–7.62, 7.58-7.53, 7.47-7.42, 6.95-6.92 (m, 14H, arom CH). ³¹P{¹H} NMR (CH₃OD): δ /ppm = 33.1.

Synthesis of O=PPh₂(4-C₆H₄OCO-ASP), O=L2

Chart S11. Structure of O=L2 (numbering refers to carbon atoms).



A suspension of O=PPh₂(4-C₆H₄OH) (150 mg, 0.510 mmol) in CH₂Cl₂ (20 mL) was treated with Et₃N (0.10 mL, 0.72 mmol) and ASP-COCl, freshly prepared from ASP-CO₂H (110 mg, 0.611 mmol) as described above for the synthesis of L2. The mixture was allowed to stir at room temperature for 20 hours, then the volatiles were removed in vacuo. The residue was charged on a silica column: after washings with petroleum ether/diethyl ether, the fraction corresponding to **O=L2** was collected by using a mixture of diethyl ether and acetone (1:1 v/v) as eluent. The product was isolated as a colourless sticky solid after removal of the volatile materials in vacuo. Yield 175 mg, 75%. Anal. calcd. for C₂₇H₂₁O₅P: C, 71.05; H, 4.64. Found: C, 70.66; H, 4.75. IR (solid state): $\tilde{v}/cm^{-1} = 3058w$, 2981w, 1766m ($v_{C9=0}$), 1742s ($v_{C2=0}$), 1605m, 1592m, 1484m, 1451w-m, 1437m, 1397w, 1367w-m, 1287m, 1244s, 1185vs, 1166vs (vP=O), 1118vs, 1070s, 1038vs, 1015s, 961w, 914s, 884m, 841w, 804w, 787w, 750m, 726s, 694vs. ¹H NMR (CDCl₃): δ/ppm = 8.23 (m, 1H, C7-H), 7.79–7.66 (m, 7H, arom CH), 7.59 (m, 2H, arom CH), 7.50 (m, 4H, arom CH), 7.41 (m, 1H, arom CH), 7.31 (m, 2H, arom CH), 7.20 (m, 1H, arom CH), 2.32 (s, 3H, C1-H). ¹³C{¹H} NMR $(CDCl_3)$: $\delta/ppm = 169.6 (C2), 162.4, (C9), 153.5, 151.3 (C10 and C3), 135.0 (C6), 133.8 (d, {}^2J_{CP} =$ 10.4 Hz, C12), 132.1 (d, ${}^{2}J_{CP} = 8.9$ Hz, C15), 132.0 (d, ${}^{1}J_{CP} = 104$ Hz, C14), 130.3 (d, ${}^{1}J_{CP} = 106$ Hz, C13), 128.6 (C17), 128.1 (C16), 126.3 (C4), 124.2 (C5), 122.0 (d, ${}^{3}J_{CP} = 13.4$ Hz, C11), 21.0 (C1). ${}^{31}P{}^{1}H$ NMR (CDCl₃): $\delta/ppm = 28.7$.

Synthesis and characterization of ruthenium compounds

Synthesis of [(η⁶-*p*-cymene)RuCl₂(κ*P*-PPh₂(4-C₆H₄OH))], 1

Chart S12. Structure of 1 (numbering refers to carbon atoms).



The title compound was prepared according to a slightly modified literature procedure.⁷ In a 100 mL round bottom flask, PPh₂(4-C₆H₄OH) (500 mg, 1.80 mmol), $[(\eta^6-p-\text{cymene})\text{RuCl}_2]_2$ (516 mg, 0.843 mmol) and CH₂Cl₂ (20 mL) were introduced. The resulting brick red solution was stirred at room temperature and the precipitation of an orange compound began shortly afterwards. After 14 hours, the suspension was rapidly filtered and the orange solid was washed with Et₂O and dried in vacuo (45°C). Yield: 895 mg, 91%. Orange crystals of 1·H₂O·DMSO were grown in a DMSO or a DMSO/Me₂CO solution settled aside at room temperature. Orange crystals of 1·CHCl₃ were obtained by slow hexane diffusion in a chloroform solution of 4 settled aside at room temperature. The compound is soluble in DMSO, scarcely soluble (CH₂Cl₂, MeOH, acetone) or completely insoluble (Et₂O, hexane) in other common organic solvents. Anal. calcd. for C₂₈H₂₉Cl₂OP₂Ru: C, 54.64; H, 4.75. Found: C, 54.49; H, 4.80. Melting point: 148°C (dec.). IR (solid state): $\tilde{v}/cm^{-1} =$ 3267w-br (v_{OH}), 3094-3047w, 2981m, 2971m, 2872w, 1597s, 1579m, 1541w, 1499s, 1481m, 1470m, 1438m, 1419m, 1388m, 1381m, 1360w, 1270s, 1206m, 1178s, 1159w, 1114w, 1088s, 1057m, 1033w, 998w, 965w, 938w, 898w, 869w, 860w, 833s, 816m, 802w, 747m, 704m-sh, 696s. ¹H NMR (DMSO-d₆): δ /ppm = 9.98 (s, 1H, OH), 7.78-7.65 (m, 4H, C9-H), 7.57 (*pseudo-t*, ³J_{HH} = ${}^{3}J_{\text{HP}} = 8.3 \text{ Hz}, 2\text{H}, \text{C13-H}), 7.48-7.28 \text{ (m, 6H, C10-H and C11-H)}, 6.79 \text{ (d, }{}^{3}J_{\text{HH}} = 7.4 \text{ Hz}, 2\text{H}, \text{C14-}$ H), 5.29 (d, ${}^{3}J_{\text{HH}} = 6.1$ Hz, 2H, C4), 5.20 (d, ${}^{3}J_{\text{HH}} = 5.8$ Hz, 2H, C3), 2.48* (hept, ${}^{3}J_{\text{HH}} = 6.7$ Hz, C6-H), 1.75 (s, 3H, C1-H), 0.95 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H, C7-H). *partially overlapped with DMSO signal. ¹³C{¹H} NMR (DMSO-d₆): δ /ppm = 159.2 (C15), 136.1 (d, ²J_{CP} = 10.6 Hz, C13), 134.9 (d, ${}^{1}J_{CP} = 44.8 \text{ Hz}, C8$, 133.8 (d, ${}^{2}J_{CP} = 9.2 \text{ Hz}, C9$), 129.8 (C11), 127.6 (d, ${}^{3}J_{CP} = 9.6 \text{ Hz}, C10$), 122.2 (d, ${}^{1}J_{CP} = 50.9$ Hz, C12), 114.8 (d, ${}^{3}J_{CP} = 10.7$ Hz, C14), 108.4 (C5), 95.1 (C2), 89.3 (C3), 86.6 (d, $^{2}J_{CP} = 4.8 \text{ Hz}, C4$, 29.7 (C6), 21.4 (C7), 17.1 (C1). $^{31}P{^{1}H}$ NMR (DMSO-d₆): $\delta/\text{ppm} = 22.9 \text{ ppm}.$

Synthesis of [(η⁶-*p*-cymene)RuCl₂(κ*P*-PPh₂(4-C₆H₄OCO-ASP))], 2

Chart S13. Structure of 2 (numbering refers to carbon atoms).



A CH₂Cl₂ solution (15 mL) of ASP-COCl (129 mg, 0.650 mmol), freshly prepared according to the procedure described above for the synthesis of L2, was treated with 1 (320 mg, 0.547 mmol) and then with Bu₃N (0.19 mL, 0.813 mmol). The orange suspension quickly turned into a dark red solution. After 24 hours, the product was precipitated with diethyl ether (ca. 30 mL) and isolated; the volatiles were removed in vacuo, thus affording a dark orange oily residue. The residue was charged on a silica column: Et₂O was eluted in order to remove impurities, then a red band, corresponding to 2, was collected by using neat CH₂Cl₂ as eluent. The product was recovered as a red powder upon removal of the volatiles under reduced pressure. Yield 236 mg, 58%. Crystals suitable for X-ray analysis were collected from a dichloromethane solution layered with diethyl ether and stored at -30 °C. The compound is soluble in DMSO and chlorinated solvents and insoluble in hexane and water. Anal. calcd. for C₃₇H₃₅Cl₂O₄PRu: C, 59.52; H, 4.72. Found: C, 59.6; H, 4.8. Melting point: 125°C (dec.). IR (solid state): $\tilde{v}/cm^{-1} = 3057w$, 2961w, 1765m-sh ($v_{C16=O}$), 1741s-br (v_{C23=O}), 1606w, 1589w, 1482m, 1450w-m, 1434m, 1367w-m, 1286m, 1243m-s, 1206s, 1188vs, 1168vs, 1111w, 1091m, 1037m, 1013w-m, 913w-m, 883w, 841w, 800w, 748m-s, 726w, 695vs, 655w. ¹H NMR (CDCl₃): δ /ppm = 8.15 (dd, ³J_{HH} = 7.9 Hz, ⁴J_{HH} = 1.6 Hz, 1H, C18-H), 7.90 $(dd, J = 9.8, 8.9 Hz, 2H, C13-H), 7.84 (ddd, J = 10.3, 7.8, 1.6 Hz, 4H, C9-H), 7.62 (td, {}^{3}J_{HH} = 7.9 Hz)$ Hz, ⁴*J*_{HH} = 1.6 Hz, 1H, C20-H), 7.42–7.33 (m, 7H, C10-H, C11-H and C19-H), 7.17–7.13 (m, 3H, C14-H and C21-H), 5.20 (d, ${}^{3}J_{HH} = 6.1$ Hz, 2H, C4-H), 5.02 (d, ${}^{3}J_{HH} = 5.5$ Hz, 2H, C3-H), 2.81 (hept, ${}^{3}J_{HH} = 6.9$ Hz, 1H, C6-H), 2.28 (s, 3H, C24-H), 1.86 (s, 3H, C1-H), 1.09 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H, C7-H). ¹³C{¹H} NMR (CDCl₃): δ /ppm = 169.7 (C23), 162.6 (C16), 152.1 (d, ⁴J_{CP} = 2.3 Hz, C15), 151.3 (C22), 136.2 (d, ${}^{2}J_{CP} = 10.4$ Hz, C13), 134.8 (C20), 134.3 (d, ${}^{2}J_{CP} = 9.5$ Hz, C9), 134.0 (d, ${}^{1}J_{CP} = 46.1$ Hz, C8), 132.3 (C18), 131.1 (d, ${}^{1}J_{CP} = 46.9$ Hz, C12), 130.5 (d, ${}^{4}J_{CP} = 2.0$ Hz, C11), 128.2 (d, ${}^{3}J_{CP}$ = 10.0 Hz, C10), 126.3 (C19), 124.2 (C21), 122.5 (C17), 121.2 (d, ${}^{3}J_{CP}$ = 10.8 Hz, C14), 111.2 (d, ${}^{2}J_{CP}$ = 2.8 Hz, C5), 96.3 (C2), 89.3 (d, ${}^{2}J_{CP}$ = 3.3 Hz, C3), 87.3 (d, ${}^{2}J_{CP}$ = 5.6 Hz, C4), 30.4 (C6), 22.0 (C7), 21.1 (C24), 17.8 (C1). ${}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 23.7 ppm$.

Synthesis of [(η⁶-p-cymene)RuCl₂(κP-PPh₂(4-C₆H₄OCO-IBU))], 3

Chart S14. Structure of 3 (numbering refers to carbon atoms).



In a 50 mL schlenk tube, (COCl)₂ (0.25 mL, 2.8 mmol) was added to a solution of IBU-CO₂H (122 mg, 0.590 mmol) in CH₂Cl₂ (7 mL). The resulting colourless solution was stirred at room temperature for 2 hours, then volatiles were carefully removed in vacuo (60°C). The colourless liquid obtained was dissolved in CH₂Cl₂ (10 mL); IR analysis of this solution confirmed the complete conversion to the acyl chloride (IBU-COCl). Therefore 1 (175 mg, 0.299 mmol) was introduced and an orange suspension was obtained. Addition of Et₃N (130 µL, 0.93 mmol) caused immediate formation of a deep red solution. The solution was stirred at room temperature overnight and the formation of a soluble Ru compound was assessed by TLC and ³¹P NMR. The solution was then extracted with H₂O (3x20 mL) and volatiles were removed in vacuo from the organic phase. The residue was dissolved in a small volume of Et₂O. Hexane addition under stirring caused the precipitation of the title compound as a red-brown powder. The suspension was filtered and the solid was washed with hexane and dried in vacuo (45°C). Yield: 137 mg, 59%. The compound is soluble in DMSO and chlorinated solvents, less soluble in Et_2O and insoluble in hexane and water. Anal. calcd. for C₄₁H₄₅Cl₂O₂PRu: C, 63.73; H, 5.87. Found: C, 63.4; H, 5.8. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3055w, 2957m, 2927w, 2868w, 1755s (v_{C=0}), 1590w, 1579w-sh, 1512w-sh, 1495m, 1483m, 1465m, 1435m, 1398w, 1382w, 1366w, 1331w, 1316w, 1280w, 1261w, 1208m, 1169s, 1134s, 1119s-sh, 1092s, 1069m, 1018m, 999w, 923w, 895w, 846m, 800m, 746m, 695s. ¹H NMR (CDCl₃): $\delta/\text{ppm} = 7.84-7.76$ (m, 6H, C9-H and C13-H), 7.41-7.32 (m, 6H, C10-H and C11-H), 7.26 (d, ${}^{3}J_{\text{HH}}$ = 7.8 Hz, 2H, C20-H), 7.12 (d, ${}^{3}J_{HH}$ = 7.9 Hz, 2H, C21-H), 6.99 (d, ${}^{3}J_{HH}$ = 7.4 Hz, 2H, C14-H), 5.18 (d, ${}^{3}J_{HH} = 3.2$ Hz, 2H, C4-H), 4.98 (d, ${}^{3}J_{HH} = 5.0$ Hz, 2H, C3-H), 3.91 (q, ${}^{3}J_{HH} = 7.1$ Hz, 1H, C17-H), 2.83 (hept, ${}^{3}J_{HH} = 6.8$ Hz, 1H, C6-H), 2.45 (d, ${}^{3}J_{HH} = 7.1$ Hz, 2H, C23-H), 1.84 (s, 3H, C1-H), 1.90–1.80 (m, ${}^{3}J_{\text{HH}} = 6.6$ Hz, 1H, C24-H), 1.58 (d, ${}^{3}J_{\text{HH}} = 7.1$ Hz, 3H, C18-H), 1.09 (d, ${}^{3}J_{\text{HH}} = 7.1$ Hz, 2H, C18-H), 1.09 (d, {}^{3}J_{\text{HH}} = 7.1 Hz, 2H, C18-H), 1.09 (d, {}^{3}J_{\text{HH}} = 7.1 Hz, 2H, C18-H), 1.09 (d, {}^{3}J_{\text{HH}} = 7.1 Hz, 2H, C18-H), 1.09 (d, {}^{3}J_{\text{H}} = 7.1 Hz, 2H, C18-H), 1.09 (d, {}^{3}J_{\text{H}} = 7.1 H 6.9 Hz, 6H, C7-H), 0.90 (d, ${}^{3}J_{HH} = 6.6$ Hz, 6H, C25-H). ${}^{13}C{}^{1}H{}$ NMR (CDCl₃): δ /ppm = 172.9 (C16), 152.5 (d, ${}^{4}J_{CP}$ = 2.9 Hz, C15), 141.1 (C22), 137.0 (C19), 135.9 (d, ${}^{2}J_{CP}$ = 10.4 Hz, C13), 134.3 (d, ${}^{2}J_{CP} = 9.4$ Hz, C9), 134.0 (d, ${}^{1}J_{CP} = 45.5$ Hz, C8), 130.8 (d, ${}^{1}J_{CP} = 47.4$ Hz, C12), 130.4 (d, ${}^{4}J_{CP} = 1.1$ Hz, C11), 129.7 (C21), 128.1 (d, ${}^{3}J_{CP} = 9.9$ Hz, C10), 127.3 (C20), 121.1 (d, ${}^{3}J_{CP} = 10.7$ Hz, C14), 111.3 (d, ${}^{2}J_{CP} = 2.7$ Hz, C5), 96.2 (C2), 89.3–89.2 (m, C3), 87.4–87.2 (m, C4), 45.4 (C17), 45.1 (C23), 30.4 (C6 or C24), 30.3 (C6 or C24), 22.5 (C25), 22.0 (C7), 18.5 (C18), 17.9 (C1). ${}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 23.6$.

Synthesis of [(η⁶-p-cymene)RuCl₂(κP-PPh₂(4-C₆H₄OCO-EA))], 4

Chart S15. Structure of 4 (numbering refers to carbon atoms).



Preparation via acyl chloride. In a 50 mL Schlenk tube (COCl)₂ (0.10 mL, 1.2 mmol) was added to a solution of EA-CO₂H (65 mg, 0.21 mmol) in CHCl₃ (7 mL). The colourless solution was heated under reflux for 1 hour then volatiles were carefully removed in vacuo (50°C). The pale yellow oily residue obtained was dissolved in CH₂Cl₂ (10 mL); IR analysis of this solution confirmed the complete conversion to the acyl chloride (EA-COCl). Therefore **1** (103 mg, 0.176 mmol) was introduced and an orange suspension was obtained. Addition of Et₃N (50 µL, 0.36 mmol) led to the formation of a red solution in 20 minutes. The reaction mixture was stirred at room temperature overnight then volatiles were removed in vacuo. The residue was dissolved in a small volume of CH₂Cl₂/ⁱPrOH (1:1 ν/ν) then hexane was added under stirring. The title compound precipitated as a brown-red powder. The suspension was filtered and the solid was washed with Et₂O and dried in vacuo (40°C). Yield: 98 mg, 64%.

Preparation via EDCI-mediated coupling: In a 25 mL Schlenk tube, EA-CO₂H (108 mg, 0.355 mmol), **1** (84 mg, 0.143 mmol), CH₂Cl₂ (7 mL), EDCI·HCl (86 mg, 0.554 mmol) and DMAP (5 mg, 0.041 mmol) were introduced in this order. The resulting orange suspension turned into a red solution in a few minutes. The solution was stirred at room temperature for 24 hours and the formation of a soluble Ru compound was assessed by TLC. Therefore volatiles were removed in vacuo. The residue was dissolved in CH₂Cl₂ and extracted with H₂O (3x30mL). Volatiles were removed in vacuo from the organic phase and the residue was suspended in Et₂O (20 mL). The suspension was filtered and the resulting brown solid was washed with Et₂O and dried in vacuo (40°C). Yield: 77 mg, 64%.

Preparation via coordination of phosphinoester ligand: In a 50 mL round bottom flask, L4 (275 mg, 0.488 mmol), $[(\eta^6-p-cymene)RuCl_2]_2$ (119 mg, 0.194 mmol) and CHCl_3 (20 mL) were introduced and the resulting brick red solution was heated at reflux for 30 hours. The final dark red solution was cooled to room temperature and then volatiles were removed in vacuo. The residue was suspended in Et₂O (15 mL) with vigorous stirring and filtered. The solid was re-dissolved in a

small volume of CH₂Cl₂ then ^{*i*}PrOH (1-2 mL) and hexane were added with intense stirring. The title compound precipitated as a brown powder. The suspension was filtered and the solid was washed with hexane and dried in vacuo (40°C). Yield: 219 mg, 65%.

The compound is soluble in chlorinated solvents and DMSO, less soluble in 'PrOH and Et₂O, insoluble in hexane and water. Anal. calcd. for C₄₁H₃₉Cl₄O₄PRu: C, 56.63; H, 4.52. Found: C, 56.4; H, 4.5. Melting point: 114°C (dec.). IR (solid state): $\tilde{v}/cm^{-1} = 3057w$, 2981s, 2972s-sh, 2889m, 1778m (v_{C16=0}), 1664m (v_{C24=0}), 1584m (v_{C25=C26}), 1494m-sh, 1495w-sh, 1482m-sh, 1469m, 1435m, 1383s, 1339w, 1293m, 1259m, 1206m, 1169s, 1157s, 1120m, 1074s, 1017m, 1000m, 952m, 895w, 843w, 801m, 770w-sh, 747m, 695s, 666w. ¹H NMR (CDCl₃): δ/ppm = 7.88 (*pseudo*t, ${}^{3}J_{\text{HH}} = {}^{3}J_{\text{HP}} = 9$ Hz, 2H, C13-H), 7.82 (*pseudo*-t, ${}^{3}J_{\text{HH}} = {}^{3}J_{\text{HP}} = 9$ Hz, 4H, C9-H), 7.45–7.32 (m, 6H, C10-H and C11-H), 7.15 (d, ${}^{3}J_{\text{HH}} = 8.0$ Hz, 1H, C22-H), 7.12-7.07 (m, 2H, C14-H), 6.87 (d, ${}^{3}J_{\text{HH}} = 8.0 \text{ Hz}, 1\text{H}, C23-\text{H}), 5.93 \text{ (s, 1H, C26-H)}, 5.58 \text{ (s, 1H, C26-H')}, 5.19 \text{ (d, }{}^{3}J_{\text{HH}} = 5.0, 2\text{H}, C4-$ H), 5.00 (d, ${}^{3}J_{\text{HH}} = 5.0$ Hz, 2H, C3-H), 4.97 (s, 2H, C17), 2.80 (hept, ${}^{3}J_{\text{HH}} = 6.1$ Hz, 1H, C6-H), 2.44 (q, ${}^{3}J_{HH} = 6.9$ Hz, 2H, C27-H), 1.84 (s, 3H, C1-H), 1.12 (t, ${}^{3}J_{HH} = 7.0$ Hz, 3H, C28-H), 1.08 (d, ${}^{3}J_{\text{HH}} = 5.9 \text{ Hz}, 6\text{H}, \text{C7-H}$). ${}^{13}\text{C}\{{}^{1}\text{H}\}$ NMR (CDCl₃): $\delta/\text{ppm} = 195.7$ (C24), 165.9 (C16), 155.2 (C18), 151.2 (C15), 150.0 (C25), 136.1 (d, ${}^{2}J_{CP} = 10.3$ Hz, C13), 134.1 (d, ${}^{2}J_{CP} = 9.5$ Hz, C9), 134.0 (C19), 133.8 (d, ${}^{1}J_{CP} = 47.7$ Hz, C8), 131.5 (C20), 131.3 (d, ${}^{1}J_{CP} = 46.0$ Hz, C12), 130.5 (C11), 128.8 (C26), 128.1 (d, ${}^{3}J_{CP} = 9.8$ Hz, C10), 126.9 (C22), 123.4 (C21), 120.6 (d, ${}^{3}J_{CP} = 10.3$ Hz, C14), 111.3 (C23), 111.1 (C5), 96.2 (C2), 89.1 (C3), 87.2 (d, ${}^{2}J_{CP} = 4.8$ Hz, C4), 66.5 (C17), 30.2 (C6), 23.3 (C27), 21.8 (C7), 17.8 (C1), 12.4 (C28). ${}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 24.0$.

Synthesis of [(η⁶-*p*-cymene)RuCl₂(κ*P*-PPh₂(4-C₆H₄OCO-IM))], 5

Chart S16. Structure of 5 (numbering refers to carbon atoms).



In a 50 mL schlenk tube $(COCl)_2$ (0.15 mL, 1.7 mmol) was added to a solution of IM-CO₂H (109 mg, 0.304 mmol) in CH₂Cl₂ (7 mL). The resulting pale yellow solution was stirred at room temperature for 2 hours. Volatiles were then carefully removed in vacuo (50 °C), thus yielding a pale yellow solid. IR analysis of this material (solid state and CH₂Cl₂ solution) confirmed the complete conversion of IM-CO₂H into the corresponding acyl chloride (IM-COCl). Therefore **1**

(146 mg, 0.249 mmol) and CH₂Cl₂ (8 mL) were introduced and an orange suspension was obtained. Addition of Et₃N (88 µL, 0.63 mmol) caused immediate formation of a deep red solution. The solution was stirred at room temperature overnight and the formation of a soluble Ru compound was assessed by TLC and ³¹P NMR. Therefore, the solution was extracted with HCl 10⁻³ M in H₂O (3x20 mL). Volatiles were removed in vacuo from the organic phase and the residue was suspended in Et₂O/hexane (1:1 v/v, 20 mL). The suspension was filtered and the brown-red powder was washed with hexane and dried in vacuo (45°C). Yield: 179 mg, 78%. The compound is soluble in chlorinated solvents and DMSO, less soluble in Et₂O, insoluble in hexane and water. Anal. calcd. for C₄₇H₄₃Cl₃NO₄PRu: C, 61.08; H, 4.69. Found: C, 61.2; H, 4.7. IR (solid state): $\tilde{\nu}/cm^{-1} = 3056w$, 2960w, 2928w, 2872w, 2833w, 1960w, 1756m (v_{C16=0}), 1681s (v_{C28=0}), 1590m, 1608m-sh, 1478s, 1456m, 1435s, 1398m, 1369m-sh, 1356s, 1317s, 1290m-sh, 1210s, 1169s, 1121s, 1088s, 1065s, 1033m, 1014s, 996m, 924m, 913m, 835m, 801m, 753s, 728m-sh, 694s. ¹H NMR (CDCl₃): δ/ppm = 7.87–7.77 (m, 6H, C9-H and C13-H), 7.66 (d, ${}^{3}J_{HH} = 8.4$ Hz, 2H, C30-H), 7.47 (d, ${}^{3}J_{HH} = 8.4$ Hz, 2H, C31-H), 7.42–7.34 (m, 6H, C10-H and C11-H), 7.04 (d, ${}^{3}J_{HH} = 7.6$ Hz, 2H, C14-H), 7.01 (d, ${}^{4}J_{\rm HH} = 2.3$ Hz, 1H, C20-H), 6.87 (d, ${}^{3}J_{\rm HH} = 9.0$ Hz, 1H, C24-H), 6.67 (dd, ${}^{3}J_{\rm HH} = 9.0$ Hz, ${}^{4}J_{\rm HH} = 2.3$ Hz, 1H, C23-H), 5.19 (d, ${}^{3}J_{HH} = 5.8$ Hz, 2H, C3-H or C4-H), 4.98 (d, ${}^{3}J_{HH} = 5.6$ Hz, 2H, C3-H or C4-H), 3.88 (s, 2H, C17-H), 3.82 (s, 3H, C22-H), 2.82 (hept, ${}^{3}J_{HH} = 6.8$ Hz, 1H, C6-H), 2.43 (s, 3H, C27-H), 1.85 (s, 3H, C1-H), 1.09 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H, C7-H). ${}^{13}C{}^{1}H$ NMR (CDCl₃): δ /ppm = 168.9 (C16 or C28), 168.4 (C16 or C28), 156.3 (C21), 152.2 (C15), 139.5 (C32), 136.3 (C19), 136.1 (d, ${}^{2}J_{CP} = 10.4$ Hz, C13-H), 134.3 (d, ${}^{2}J_{CP} = 9.3$ Hz, C9-H), 134.0 (d, ${}^{1}J_{CP} = 45.4$ Hz, C8-H), 133.9 (C29), 131.3 (C30), 131.0 (C26), 130.5 (C25), 130.4 (C11), 129.3 (C31), 128.2 (d, ${}^{3}J_{CP} = 9.9$ Hz, C10), 120.9 (d, ${}^{3}J_{CP} = 10.8$ Hz, C14), 115.1 (C24), 111.9 (C18), 111.8 (C23), 111.3 (C5), 101.4 (C20), 96.3 (C2), 89.2 (d, ${}^{2}J_{CP}$ = 2.0 Hz, C3 or C4), 87.3 (d, ${}^{2}J_{CP}$ = 5.3 Hz, C3 or C4), 55.9 (C22), 30.7 (C17), 30.4 (C6), 22.0 (C7), 17.9 (C1), 13.5 (C27). ${}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 23.8$.

Synthesis of [(η⁶-*p*-cymene)RuCl₂(κ*P*-PPh₂(4-C₆H₄OCO-DF))], 6

Chart S17. Structure of 6 (numbering refers to carbon atoms).



A solution of DF-CO₂H (134 mg, 0.452 mmol) in CH₂Cl₂ (10 mL) was treated with 1 (250 mg, 0.428 mmol), EDCI-HCl (104 mg, 0.543 mmol) and DMAP (8.0 mg, 0.068 mmol) in the order given. The orange suspension quickly turned into a dark red solution. After 24 hours, the volatiles were removed in vacuo and the residue was charged on a silica column. Mixtures of petroleum ether and Et₂O were used to elute impurities, then an orange band, corresponding to 6, was collected by using neat CH₂Cl₂ as eluent. The product was recovered as an orange powder upon removal of the solvent in vacuo. Yield 221 mg, 60%. The compound is soluble in DMSO and chlorinated solvents and insoluble in hexane and water. Anal. calcd. for C₄₂H₃₈Cl₄NO₂PRu: C, 58.48; H, 4.44. Found: C, 58.4; H, 4.3. Melting point: 127° C (dec.). IR (solid state): v = 3351br (v_{NH}) , 3056w, 2957w, 2124w, 1746m $(v_{C=0})$, 1588w-m, 1495m-s, 1451s, 1435s, 1292w-m, 1207s, 1168vs, 1129vs, 1092s, 1017m-s, 1013w-m, 922w, 846w-m, 799w-m, 774m-s, 745vs, 695vs, 663w-m cm⁻¹. ¹H NMR (CDCl₃): δ /ppm = 7.88–7.78 (m, 6H, C9-H and C13-H), 7.41–7.30 (m, 9H, C10-H, C11-H, C19-H and C26-H), 7.15 (td, ${}^{3}J_{HH} = 7.8$ Hz, ${}^{4}J_{HH} = 1.0$ Hz, 1H, C21-H), 7.10 (dd, ${}^{3}J_{\text{HH}} = 8.5 \text{ Hz}, J = 1.3 \text{ Hz}, 2\text{H}, C14\text{-H}), 7.00 \text{ (t, } {}^{3}J_{\text{HH}} = 7.4 \text{ Hz}, 1\text{H}, C27\text{-H}), 6.98 \text{ (t, } {}^{3}J_{\text{HH}} = 8.0 \text{ Hz},$ 1H, C20-H), 6.65 (s, 1H, NH), 6.57 (d, ${}^{3}J_{HH} = 8.2$ Hz, 1H, C22-H), 5.18 (d, ${}^{3}J_{HH} = 6.0$ Hz, 2H, C3-H or C4-H), 5.00 (d, ${}^{3}J_{HH} = 5.7$ Hz, 2H, C3-H or C4-H), 4.03 (s, 2H, C17-H), 2.82 (hept, ${}^{3}J_{HH} = 6.7$ Hz, 1H, C6-H), 1.86 (s, 3H, C1-H), 1.09 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H, C7-H). ${}^{13}C{}^{1}H$ NMR (CDCl₃): $\delta/\text{ppm} = 170.3 \text{ (C16)}, 152.2 \text{ (d, } {}^{4}J_{\text{CP}} = 2.2 \text{ Hz}, \text{C15)}, 142.8 \text{ (C23)}, 137.9 \text{ (C24)}, 135.9 \text{ (d, } {}^{2}J_{\text{CP}} = 10.4 \text{ Hz}, 135.9 \text{ (d, } {}^{2}J_{\text{CP}} = 10.4 \text{ H$ Hz, C13), 134.4 (d, ${}^{2}J_{CP} = 9.5$ Hz, C9), 133.9 (d, ${}^{1}J_{CP} = 45.6$ Hz, C8), 132.0 (d, ${}^{1}J_{CP} = 45.6$ Hz, C12), 131.1 (C19), 130.5 (d, ${}^{4}J_{CP} = 2.1$ Hz, C11), 129.6 (C25), 129.0 (C26), 128.5 (C21), 128.2 (d, ${}^{3}J_{CP} = 8.0$ Hz, C10), 124.3 (C27), 123.9 (C18), 122.5 (C20), 121.1 (d, ${}^{3}J_{CP} = 10.6$ Hz, C14), 118.8 (C22), 111.3 (C5), 96.2 (C2), 89.3 (d, ${}^{2}J_{CP}$ = 3.2 Hz, C3 or C4), 87.2 (d, ${}^{2}J_{CP}$ = 5.4 Hz, C4 or C4), 38.7 (C17), 30.4 (C6), 22.0 (C7), 17.9 (C1). ${}^{31}P{}^{1}H{}$ NMR (CDCl₃): $\delta/ppm = 23.6$.

Synthesis of [(η⁶-*p*-cymene)RuCl₂(κ*P*-PPh₂(4-C₆H₄OCO-VP))], 7

Chart S18. Structure of 7 (numbering refers to carbon atoms).



In a 25 mL Schlenk tube, CH_2Cl_2 (7 mL), VP-CO₂H (55 µL, 0.35 mmol), **1** (82 mg, 0.087 mmol), EDCI·HCl (85 mg, 0.54 mmol) and DMAP (5 mg, 0.04 mmol) were introduced in the order given.

The resulting orange suspension turned into a red solution in a few minutes. The solution was stirred at room temperature for additional 24 hours, and the formation of a soluble Ru compound was assessed by TLC. Therefore volatiles were removed in vacuo; the residue was dissolved in CH₂Cl₂ and extracted with H₂O (3x30mL). Volatiles were removed in vacuo from the organic phase and the residue was suspended in hexane (20 mL). The suspension was cooled to -20°C, then filtered and the resulting red-brown solid was washed with a small volume of cold hexane and dried in vacuo (40°C). Yield: 70 mg, 71%. The compound is soluble in DMSO, chlorinated solvents and Et₂O, less soluble in hexane and insoluble in water. Anal. calcd. for C₃₆H₄₃Cl₂O₂PRu: C, 60.84; H, 6.10. Found: C, 60.9; H, 6.2. IR (solid state): $\tilde{v}/cm^{-1} = 3055w$, 2958m, 2931m, 2871m, 1751s (v_{C=0}), 1621w, 1590m, 1577w-sh, 1540w, 1495m, 1483m, 1465m, 1435s, 1397w, 1377m, 1261w, 1209m, 1193m, 1169s, 1147m-sh, 1094s, 1067m-sh, 1056m-sh, 1028m, 1017m, 999m, 975w, 923w, 873m, 848w, 800m, 746s, 695s. ¹H NMR (CDCl₃): δ /ppm = 7.89–7.79 (m, 6H, C9-H and C13-H), 7.43–7.34 (m, 6H, C10-H and C11-H), 7.06 (d, ${}^{3}J_{HH} = 7.9$ Hz, 2H, C14-H), 5.20 (d, ${}^{3}J_{HH} =$ 5.9 Hz, 2H, C4-H), 5.00 (d, ${}^{3}J_{HH} = 5.7$ Hz, 2H, C3-H), 2.84 (hept, ${}^{3}J_{HH} = 6.8$ Hz, 1H, C6-H), 2.59 (m, J = 14.1, 9.3, 5.3 Hz, 1H, C17-H), 1.87 (s, 3H, C1-H), 1.78–1.66 (m, 2H, C18-H), 1.59–1.48 (m, 2H, C18-H), 1.40 (sex, ${}^{3}J_{HH} = 7.1$ Hz, 4H, C19-H), 1.10 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H, C7-H), 0.94 (t, ${}^{3}J_{\text{HH}} = 7.2 \text{ Hz}, 6\text{H}, C20\text{-H}). {}^{13}\text{C} \{{}^{1}\text{H}\} \text{ NMR (CDCl_3): } \delta/\text{ppm} = 174.8 (C16), 152.5 (d, {}^{4}J_{\text{CP}} = 2.7 \text{ Hz},$ C15), 136.0 (d, ${}^{2}J_{CP} = 10.4$ Hz, C13), 134.3 (d, ${}^{2}J_{CP} = 9.5$ Hz, C9), 134.1 (d, ${}^{1}J_{CP} = 46.4$ Hz, C8), 130.7 (d, ${}^{1}J_{CP} = 45.9$ Hz, C12), 130.4 (C11), 128.2 (d, ${}^{3}J_{CP} = 9.9$ Hz, C10), 121.2 (d, ${}^{3}J_{CP} = 10.6$ Hz, C14), 111.4 (d, ${}^{2}J_{CP} = 3.2$ Hz, C5), 96.2 (C2), 89.2 (d, ${}^{2}J_{CP} = 2.8$ Hz, C3), 87.3 (d, ${}^{2}J_{CP} = 5.5$ Hz, C4), 45.5 (C17), 34.7 (C18), 30.4 (C6), 22.0 (C7), 20.8 (C19), 17.9 (C1), 14.1 (C20). ³¹P{¹H} NMR (CDCl₃): δ /ppm = 23.6.

IR band ^[a] or NMR signal ^[b] / Compound	v(C=O) / cm ⁻¹ ester moiety	¹ H δ(OH) / ppm	13 C δ (CO ₂) / ppm ester moiety	³¹ P δ(PR ₃) / ppm
PPh ₂ (4-C ₆ H ₄ OH)	-	5.96 s-br	-	-6.8
1	-	9.98 s	-	22.9
ASP-CO ₂ H	1681s	10.7 br	170.3 / 169.9	-
2	1741m-sh	-	162.6	23.7
IBU-CO ₂ H	1712s	10.5 br	10.5 br 180.9	
3	1755s	-	172.9	23.6
EA-CO ₂ H	1724s	1724s 7.75 s-br 172.6		-
4	1778m	-	165.9	24.0
IM-CO ₂ H	1713s	n.d.	176.8	-
5	1756m	-	168.9 / 168.4	23.8
DF-CO ₂ H	1690s	10.8 br	173.9	-
6	1746m	-	170.3	23.6
VP-CO ₂ H	1702s	11.4 s-br	183.6	-
7	1751s	-	174.8	23.6

 Table S1. Comparison of IR and NMR data for complexes 1-7 and related compounds.

[a] Solid-state or liquid film (VP-CO₂H).

[b] CDCl₃ solution except 1 (DMSO-d₆ solution) and DF-CO₂H (acetone-d₆ solution)

X-ray crystallography

The diffraction experiments were carried out on a Bruker APEX II diffractometer equipped with a CCD detector and using Mo-K α radiation (Table SI2). Data were corrected for Lorentz polarization and absorption effects (empirical absorption correction SADABS⁸). The structures were solved by direct methods and refined by full-matrix least-squares based on all data using $F^{2,9}$ Hydrogen atoms were fixed at calculated positions and refined by a riding model, except O-bonded hydrogens of $1 \cdot Me_2SO \cdot H_2O$ that have been located in the Fourier map and refined isotropically using the 1.5 fold U_{iso} value of the parent atoms. The O-H distances were restrained to 0.84 Å (s.u. 0.02). All non-hydrogen atoms were refined with anisotropic displacement parameters.

	1·Me ₂ SO·H ₂ O	2
Formula	C ₃₀ H ₃₇ Cl ₂ O ₃ PRuS	C37H35Cl2O4PRu
Fw	680.59	746.59
Т, К	100(2)	293(2)
λ, Å	0.71073	0.71073
Crystal system	Triclinic	Triclinic
Space group	P1	P 1
<i>a</i> , Å	8.1267(3)	10.9850(3)
b, Å	9.0933(3)	12.0865(4)
<i>c</i> , Å	11.0788(7)	13.9883(4)
<i>α</i> , °	102.780(2)	114.0750(10)
β, °	97.314(2)	92.914(2)
γ, °	107.4730(10)	97.381(2)
Cell Volume, Å ³	744.89(6)	1670.65(9)
Z	1	2
D_c , g cm ⁻³	1.517	1.484
μ , mm ⁻¹	0.860	0.716
F(000)	350	764
Crystal size, mm	0.18×0.15×0.11	0.16×0.13×0.12
θ limits, °	1.827-26.999	1.605-25.498
Reflections collected	12584	25440
Independent reflections	$6398 [R_{int} = 0.0300]$	$6194 [R_{int} = 0.0587]$
Data / restraints /parameters	6398 / 6 / 352	6194 / 0 /406
Goodness on fit on \overline{F}^2	1.049	1.042
$R_1 (I > 2\sigma(I))$	0.0250	0.0443
wR_2 (all data)	0.0640	0.1134
Largest diff. peak and hole, e Å ⁻³	1.146 / -0.506	0.770 / -0.351

Table S2. Crystal data and experimental details for 1·Me₂SO·H₂O and 2.

Stability studies.

General procedure. Complexes 1–7 were dissolved in DMSO-d₆/D₂O 9:1 ν/ν (1.0 mL; [Ru] = 2·10⁻² mol·L⁻¹). An aliquot of the resulting solution (0.40 mL) was transferred into a NMR tube, maintained at 37°C for 72 hours and analyzed by ¹H and ³¹P{¹H} NMR spectroscopy as a function of time. The remaining solution was diluted up to 4.0 mL with DMSO/H₂O 9:1 ν/ν (final [Ru] = $3 \cdot 10^{-3}$ mol·L⁻¹), maintained at 37 °C for 72 hours and its conductivity was measured as a function of time. Parallel NMR analyses were carried out on DMSO-d₆/D₂O solutions prepared by the same procedure described above, and with the addition of NaCl (0.1 mol·L⁻¹). Values of molar conductivity (A_m) were calculated with respect to the starting material. Percent values of compounds in solution are based on ¹H NMR spectroscopy and refer to identified compounds only. NMR signals in braces {} indicate superimpositions with other species.

Reference data. NMR spectra of the following compounds were recorded in DMSO-d₆/D₂O 9:1): δ /ppm = 7.12–7.03 (m, 4H), 2.80 (hept, ${}^{3}J_{HH} = 6.9$ Hz, 1H), 2.23 (s, 3H), 1.15 (d, ${}^{3}J_{HH} = 6.9$ Hz, 6H). **ASP-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.91 (dd, J = 7.8, 1.4 Hz, 1H), 7.62 (td, J = 7.8, 1.4 Hz, 1H), 7.62 (td, J = 7.8, 1.4 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 3.61 (q, J = 7.1 Hz, 1H), 2.39 (d, J = 7.1 Hz, 2H), 1.78 (non, J = 6.7 Hz, 1H), 1.32 (d, J = 7.1 Hz, 3H), 0.83 (d, J = 6.6 Hz, 6H). **EA-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.24 (d, ${}^{3}J_{HH} = 8.6$ Hz, 1H), 7.02 (d, ${}^{3}J_{HH} = 8.7$ Hz, 1H), 6.03 (s, 1H), 5.52 (s, 1H), 4.83 (s, 2H), 2.30 (q, ${}^{3}J_{HH} = 7.1$ Hz, 2H), 1.01 (t, ${}^{3}J_{HH} = 7.4$ Hz, 3H). **IM-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.64 (pseudo-q, J = 8.7 Hz, 4H), 7.01 (d, J = 2.4 Hz, 1H), 6.92 (d, J = 9.0 Hz, 1H), 6.70 (dd, J = 9.0, 2.4 Hz, 1H), 3.74* (s), 3.64 (s, 2H), 2.19 (s, 3H). *partially overlapped with DHO signal. **DF-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.34 (d, ${}^{3}J_{HH} = 7.4$ Hz, 1H), 6.92 (d, J = 9.0 Hz, 1H), 6.70 (dd, J = 9.0, 2.4 Hz, 1H), 3.74* (s), 3.64 (s, 2H), 2.19 (s, 3H). *partially overlapped with DHO signal. **DF-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.34 (z, ${}^{3}J_{HH} = 7.4$ Hz, 3H). (z, ${}^{3}J_{HH} = 8.1$ Hz, 2H), 7.19 (d, ${}^{3}J_{HH} = 7.3$ Hz, 1H), 7.17 (t, ${}^{3}J_{HH} = 7.9$ Hz, 1H), 7.06 (t, ${}^{3}J_{HH} = 7.7$ Hz, 1H), 6.87 (t, ${}^{3}J_{HH} = 7.4$ Hz, 1H), 7.17 (t, ${}^{3}J_{HH} = 7.9$ Hz, 1H), 7.06 (t, ${}^{3}J_{HH} = 7.7$ Hz, 1H), 6.87 (t, ${}^{3}J_{HH} = 7.4$ Hz, 1H), 7.17 (t, ${}^{3}J_{HH} = 7.9$ Hz, 1H), 7.06 (t, ${}^{3}J_{HH} = 7.7$ Hz, 1H), 6.87 (t, ${}^{3}J_{HH} = 7.4$ Hz, 1H), 6.27 (d, ${}^{3}J_{HH} = 7.9$ Hz, 1H), 7.06 (t, ${}^{3}J_{HH} = 7.7$ Hz, 1H), 6.87 (t, ${}^{3}J_{HH} = 7.4$ Hz, 1H), 6.27 (t, ${}^{3}J_{HH} = 7.9$ Hz, 1H), 3.67

(s, 2H). **VP-CO₂H**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 2.26–2.16 (m, 1H), 1.50–1.38 (m, 2H), 1.38–1.27 (m, 2H), 1.21 (sex, ³J_{HH} = 6.8 Hz, 4H), 0.82 (t, ³J_{HH} = 7.1 Hz, 6H).

Compound 1. Data are compiled in Table S3 while NMR detected species are shown in Scheme S11. **1**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.74–7.64 (m, 4H), 7.58–7.52 (m, 2H), 7.44–7.32 (m, 6H), 6.77 (d, *J* = 7.3 Hz, 2H), 5.26 (d, *J* = 6.1 Hz, 2H), 5.18 (d, *J* = 5.8 Hz, 2H), 1.73 (s, 3H), 0.94 (d, *J* = 6.9 Hz, 6H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.0. **S**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 5.79 (d, *J* = 6.1 Hz, 1H), 5.74 (d, *J* = 6.7 Hz, 1H), 2.07 (s, 3H), 1.18 (d, *J* = 7.0 Hz, 6H). **L1**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.61–7.54 (m), {7.43–7.34 (m)}, 7.21–7.14 (m, 4H), 6.80 (d, *J* = 8.2 Hz, 2H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -8.5 ppm. **O=L1**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 6.91 (dd, 2H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 36.6 (72 h).

Scheme S1 and Table S3. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 1 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.

Ph Ph Cl Cl Cl Cl OH OH	Ph_{P} P	Ph Ph-P=O OH	
-------------------------	--	--------------------	--

1	S		L	0=L1	
time / hours		0.5	24	48	72
Λ _m / S·cm ² ·mol ⁻¹		5.9	7.9	10	13
	1	82 (91)	67 (65)	47 (45)	33 (33)
% NMR (NaCl experiment)	S	3 (2)	1 (0)	0 (0)	0 (0)
	L1	0 (1)	6 (11)	17 (21)	24 (27)
	O=L1	8 (1)	10 (3)	10 (5)	10 (6)
	<i>p</i> -cymene	7 (5)	16 (21)	26 (29)	33 (34)

Compound **2**. Data are compiled in Table S4 while NMR detected species are shown in Scheme SI2. **2**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 8.13 (d, *J* = 6.5 Hz, 1H), 7.83 (t, *J* = 9.2 Hz, 2H), 7.79–7.73 (m, 4H), 7.72–7.64 (m, 1H), 7.52–7.38 (m, 7H), 7.30 (d, *J* = 8.0 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 2H), 5.29 (d, *J* = 6.3 Hz, 2H), 5.26 (d, *J* = 5.6 Hz, 2H), 2.22 (s, 3H), 1.76 (s, 3H), 0.93 (d, *J* = 6.9 Hz, 6H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.8. **L2**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = {8.13}, {7.79–7.73}, {7.72–7.64}, 7.62–7.54 (m), {7.52–7.38}, 7.34 (d, *J* = 8.5 Hz), 7.29–7.24 (m), {2.21 (s)}. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -7.8. **O=L2**. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 26.6. All ¹H signals of **O=L2** are superimposed to those belonging to **L2**. Therefore, only the percent value for the total ¹H integral (**L2** + **O=L2**) is given.

Scheme S2 and Table S4. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 2 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



time / hou	ırs	0	6	24	48	72
$\Lambda_{\rm m}$ / S·cm ² ·mol ⁻¹		7.7	11	12	12	14
	2	71 (72)	63 (61)	52 (57)	40 (45)	30 (35)
	1	10 (15)	12 (13)	11 (12)	9 (11)	7 (8)
(NaCl experiment)	S	5 (5)	4 (5)	1 (3)	0 (1)	0 (0)
	L2 + O=L2	11 (4)	13 (13)	19 (13)	27 (18)	32 (28)
	<i>p</i> -cymene	3 (4)	8 (8)	17 (15)	24 (25)	31 (29)

Compound 3. Data are compiled in Table S5 while NMR detected species are shown in Scheme SI3. **3.** ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.78–7.66 (m, 6H), 7.47–7.35 (m, 6H), 7.26 (d, *J* = 7.4 Hz, 2H), 7.14 (d, *J* = 7.2 Hz, 2H), 7.01 (d, *J* = 8.0 Hz, 2H), 5.27 (d, *J* = 5.0 Hz, 2H), 5.22 (d, *J* = 5.5 Hz, 2H), 4.01 (dd, *J* = 13.8, 6.6 Hz, 1H), 2.40 (d, *J* = 6.9 Hz, 2H), 1.81–1.75 (m, 1H), 1.73 (s, 3H), 1.45 (d, *J* = 6.8 Hz, 3H), 0.91 (d, *J* = 6.7 Hz, 6H), 0.82 (d, *J* = 6.3 Hz, 6H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.7. L3. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.67–7.52 (m, 6H), {7.47–7.35 (m, 4H)}, {7.29–7.23 (m, 4H)}, 7.23–7.18 (m, 2H), {7.16–7.12 (m, 2H)}, {4.08–3.99 (m, 1H)}, {2.40 (d, 2H)}, {1.81–1.75 (m, 1H)}, {1.49–1.44 (m, 3H)}, {0.82 (d, 6H)}. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 26.5. All ¹H signals of **O=L3** are superimposed to those belonging to L3. Therefore, only the percent value for the total ¹H integral (L3 + O=L3) is given. Minor P-containing species: ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 38.1 (48 h).

Scheme S3 and Table S5. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 3 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



time / hours		0.5	24	48	72
Λ _m / S·cm ² ·mol ⁻¹		7.9	10	14	-
3 % NMR S		85 (84)	64 (74)	44 (50)	34 (42)
		5 (4)	1 (1)	0 (0)	0 (0)
(NaCl experiment)	L3 + O=L3	8 (10)	22 (12)	33 (29)	38 (34)
	<i>p</i> -cymene	2 (2)	13 (13)	23 (21)	28 (24)

Compound 4. Data are compiled in Table S6 while NMR detected species are shown in Scheme S14. 4. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.79 (t, *J* = 9.1 Hz, 2H), 7.76–7.69 (m, 4H), 7.49–7.37 (m, 6H), 7.30 (pseudo-q, *J* = 8.6 Hz, 2H), 7.20 (d, *J* = 7.8 Hz, 2H), 6.06 (s, 1H), 5.54 (s, 1H), 5.30 (s, 2H), 5.28 (d, *J* = 6.8 Hz, 2H), 5.24 (d, *J* = 5.8 Hz, 2H), 2.34 (q, *J* = 7.2 Hz, 2H), 2.50–2.43* (m, *J* = 6.9 Hz), 1.74 (s, 3H), 1.05 (t, *J* = 7.4 Hz, 3H), 0.91 (d, *J* = 6.9 Hz, 6H). *partially overlapped with DMSO signal. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.8. L4. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.69-7.52 (m), {7.33-7.28 (m)}, {6.06 (s)}, {5.54 (s)}, 5.33 (s), {2.34 (q)}, {1.05 (t)}. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -7.5. O=L4. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 26.5. All ¹H signals of O=L4 are superimposed to those belonging to L4. Therefore, only the percent value for the total ¹H integral (L4+ O=L4) is given. Minor P-containing species: ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 27.2 (48 h), 22.4 (48-72 h).

Scheme S4 and Table S6. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 4 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



Compound 5. Data are compiled in Table S7 while NMR detected species are shown in Scheme SI5. **5**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.80–7.68 (m, 6H), 7.64 (pseudo-q, *J* = 8.4 Hz, 4H), 7.48–7.36 (m, 6H), 7.15–7.10 (m, 3H), 6.94 (d, *J* = 8.9 Hz, 1H), 6.71 (dd, *J* = 8.7, 1.7 Hz, 1H), 5.27 (d, *J* = 6.0 Hz, 2H), 5.22 (d, *J* = 5.7 Hz, 2H), 4.05 (s, 2H), 3.74 (s, 3H), 2.49–2.43* (m, *J* = 7.2 Hz), 2.24 (s, 3H), 1.73 (s, 3H), 0.91 (d, *J* = 6.8 Hz, 6H). *partially overlapped with DMSO signal. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.7. **L5**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.764 (pseudo-q)}, {7.48-7.36 (m)}, {6.94 (d)}, {6.71 (dd)}, {4.05 (s)}, {3.74 (s)}, 2.25 (s, 3H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -7.7. **O=L5**. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 4.08 (s, 2H), 2.23 (s, 3H). ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 38.3 (72 h).

Scheme S5 and Table S7. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 5 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



time / hours		0.5	24	48	72
$\Lambda_{\rm m}$ / S·cm ² ·mol ⁻¹		24	26	28	-
5		74 (78)	63 (67)	50 (60)	40 (53)
	S	7 (7)	3 (4)	0 (1)	0 (1)
(NaCl experiment)	L5	6 (1)	7 (5)	11 (6)	16 (8)
· · · · · ·	O=L5	10 (11)	15 (16)	21 (16)	22 (17)
	<i>p</i> -cymene	3 (3)	12 (8)	18 (17)	22 (21)

Compound 6. Data are compiled in Table S8 while NMR detected species are shown in Scheme SI6. 6. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.81–7.69 (m, 6H), 7.51 (d, J = 8.1 Hz, 2H), 7.48– 7.38 (m, 6H), 7.28 (d, J = 7.3 Hz, 1H), 7.21 (t, J = 8.1 Hz, 1H), 7.15 (d, J = 7.7 Hz, 2H), 7.10–7.04 (m, 1H), 6.86 (t, J = 7.0 Hz, 1H), 6.22 (d, J = 8.0 Hz, 1H), 5.27 (d, J = 6.2 Hz, 2H), 5.23 (d, J = 5.8Hz, 2H), 4.07 (s, 2H), 2.50–2.42* (m, J = 7.0 Hz), 1.74 (s, 3H), 0.91 (d, J = 6.9 Hz, 6H). *partially overlapped with DMSO signal. ${}^{31}P{}^{1}H$ NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.6. L6. ${}^{1}H$ NMR $(DMSO-d_6:D_2O \ 9:1): \ \delta/ppm = 7.69-7.52 \ (m), \ \{7.33-7.28 \ (m)\}, \ \{6.06 \ (s)\}, \ \{5.54 \ (s)\}, \ 5.33 \ (s), \$ $\{2.34 (q)\}, \{1.05 (t)\}.^{31}P\{^{1}H\}$ NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -7.9. **O=L6**. ¹H NMR (DMSO $d_6:D_2O 9:1): \delta/ppm = 4.11 (s, 2H).^{31}P\{^{1}H\} NMR (DMSO-d_6:D_2O 9:1): \delta/ppm = 26.5.$

Scheme S6 and Table S8. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 6 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



s

1

6	

time / hours		0.5	24	48	72
Λ _m / S·cm ² ·mol ⁻¹		7.4	12	15	17
6		77 (86)	67 (52)	48 (37)	38 (29)
	1	0 (2)	2 (11)	2 (12)	2 (10)
	S	4 (5)	2 (5)	0 (4)	0 (4)
(NaCl experiment)	L6	4 (0)	9 (0)	20 (0)	23 (0)
	O=L6	7 (6)	9 (13)	8 (16)	8 (17)
	0=L1	0 (0)	0 (7)	0 (11)	0 (13)
	<i>p</i> -cymene	8 (2)	11 (12)	22 (20)	29 (27)

Compound 7. Data are compiled in Table S9 while NMR detected species are shown in Scheme SI7. 7. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.76 (t, *J* = 9.2 Hz, 2H), 7.73–7.67 (m, 4H), 7.48–7.38 (m, 6H), 7.06 (d, *J* = 7.7 Hz, 2H), 5.27 (d, *J* = 6.1 Hz, 2H), 5.22 (d, *J* = 5.9 Hz, 2H), 2.61–2.54* (m), 2.49–2.42* (m, *J* = 6.8 Hz), 1.74 (s, 3H), 1.64–1.54 (m, 2H), 1.54–1.44 (m, 2H), 1.32 (hex, *J* = 7.1 Hz, 4H), 0.91 (d, *J* = 6.9 Hz, 6H), 0.87 (t, *J* = 7.3 Hz, 6H). *superimposed to DMSO signal. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 23.8. L7. ¹H NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 7.66–7.51 (m), {7.48–7.37 (m)}, 7.31–7.26 (m, 4H), 7.25–7.19 (m, 4H), {2.60–2.55 (m)}, {1.64–1.54 (m)}, {1.54–1.44 (m)}, {1.37–1.28 (m)}, {0.88 (t, *J* = 7.3 Hz)}. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = -7.8. **O=L7**. ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 27.2. All ¹H signals of **O=L7** are superimposed to those belonging to L7. Therefore, only the percent value for the total ¹H integral (L7 + **O=L7**) is given. Minor P-containing species: ³¹P{¹H} NMR (DMSO-d₆:D₂O 9:1): δ /ppm = 38.2 (72 h).

Scheme S7 and Table S9. Molar conductivity and NMR detected species as a function of time for DMSO/water 9:1 v/v solution of 7 at 37°C. Data for analogous experiment with 0.1 M NaCl are given in parentheses.



time / hours		0	6	24	48	72
$\Lambda_{\rm m}$ / S·cm ² ·mol ⁻¹		9.1	10	11	11	12
	7		68 (72)	57 (71)	51 (51)	35 (39)
% NMR S	5 (6)	4 (5)	2 (2)	0 (0)	0 (0)	
(NaCl experiment)	L7 + O=L7	19 (15)	23 (16)	31 (16)	30 (31)	38 (33)
	<i>p</i> -cymene	2 (2)	5 (7)	10 (11)	19 (18)	27 (28)

Cell culture and cytotoxicity studies

Human ovarian carcinoma (A2780 and A2780cisR) cell lines were obtained from the European Collection of Cell Cultures (ECACC, UK). The non-tumoral human embryonic kidney (HEK-293) cell line was obtained from ATCC (Sigma, Switzerland). RPMI-1640 GlutaMAX and DMEM GlutaMAX media were obtained from Life Technologies (Switzerland), fetal bovine serum (FBS) was obtained from Sigma, penicillin streptomycin solution was obtained from Life Technologies and cisplatin was obtained from TCI.

The cells were routinely cultured in RPMI-1640 GlutaMAX (A2780 and A2780cisR) and DMEM GlutaMAX (HEK-293) medium containing 10% heat-inactivated FBS 1% and penicillin/streptomyc in solution at 37 °C and CO₂ (5%). The A2780cisR cell line was routinely treated with cisplatin (2 μ M) in the medium. The cytotoxicity of compounds was measured using the MTT assay (MTT = 3-(4.5-dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide).¹ Cells were seeded in flat-bottom 96-well plates as a suspension in medium containing 10% heatinactivated FBS and 1% penicillin/streptomycin solution (100 µL and approximately 4300 cells per well) and incubated for 24 h. Stock solutions of compounds were prepared in DMSO and were rapidly diluted in medium. The solutions were sequentially diluted (final DMSO concentration of 0.5%) to give a compound concentration range (0 μ M to 500 μ M). Cisplatin was tested as a positive control (0 to 100 μ M). The compounds were added to the pre-incubated 96-well plates in 100 μ L aliquots and the plates were incubated for 72 h. MTT (20µL, 5 mg/mL in Dulbecco's Phosphate Buffered Saline, DPBS) was added to the cells and the plates were incubated for further 4 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO (100 µL per well). The absorbance of the resulting solutions, directly proportional to the number of surviving cells, was quantified at 590 nm using a SpectroMax M5e multi-mode microplate reader and SoftMax Pro software (version 6.2.2). The percentage of surviving cells was calculated from the absorbance of wells

corresponding to the untreated control cells. The reported IC_{50} values (Table 1) are based on means from two independent experiments, each comprising four testings per concentration level.

References

- 1 M. A. Bennett and A. K. Smith, J. Chem. Soc., Dalton Trans., 1974, 233-241.
- 2 W. Willker, D. Leibfritz, R. Kerssebaum, and W. Bermel, *Magn. Reson. Chem.* 1993, **31**, 287-292.
- 3 A. Köllhofer and H. Plenio, *Chem. Eur. J.*, 2003, 9, 1416-1425.
- 4 F. Sieber, P. Wentworth Jr., J. D. Toker, A. D. Wentworth, W. A. Metz, N. N. Reed and K. D. Janda, *J. Org. Chem.*, 1999, 64, 5188-5192.
- 5 A. Burghstaler, L. O. Weigel and C. G. Shaefer, Synthesis, 1976, 767-768.
- a) X. Zhang, H. Liu, X. Hu, G. Tang, J. Zhu and Y. Zhao, *Org. Lett.*, 2011, 13, 3478–3481 b) J.
 Nithyanandhan and N. Jayaraman, *Tetrahedron*, 2005, 61, 11184–11191.
- 7 I. Angurell, C.-O. Turrin, R. Laurent, V. Maraval, P. Servin, O. Rossell, M. Seco, A.-M. Caminade and J.-P. Majoral, *J. Organomet. Chem.*, 2007, **692**, 1928–1939.
- 8 G. M. Sheldrick, *SADABS*, *Program for empirical absorption correction*, University of Göttingen, Göttingen, Germany, 1997.